Clinical Trial Update: The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the PD-1 inhibitor Pucotenlimab combined with the EGFR-ADC Becotatugvedotin for advanced cholangiocarcinoma; the study status is NOT_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Becotatugvedotin (Becotatugvedotin)
• Pucotenlimab

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING